The engineering firm, Demcon, has decided to invest in our sample preparation device, the VitroJet, based on the IP generated at Maastricht University. Higher yield in vitreous protein samples intended for the cryoTEM will lessen the bottleneck in the overall workflow. Once researchers can reliably obtain adequate thin vitreous layers proteins, it will enable them to resolve more structures in the search for cures to debilitating diseases. In the race for effective treatments, it’s paramount to understand the structure and biology behind the proteins and complexes involved.
Demcon invests in CryoSol
Feb 26, 2020 | News